二甲双胍和瑞舒伐他汀联合用于治疗初诊肥胖型2型糖尿病的疗效观察

doi:10.3969/j.issn.1006-6233.2018.02.019

摘要
图/表
参考文献
相关文章 (7)

全文: PDF (1318 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨二甲双胍和瑞舒伐他汀联合用于治疗初诊肥胖型2型糖尿病的疗效。方法: 收集2015年7月至2016年11月入院的90例初诊肥胖型2型糖尿病患者随机分为两组,对照组患者给予二甲双胍治疗,观察组患者则加服瑞舒伐他汀,比较两组患者疾病相关参数、总体治疗效果与生活质量。结果: 观察组患者治疗后BMI、SBP、FBG、2hPG、HbAlc、HOMA-IR、IMT、TC、TG与LDL-C水平组间比较均低于对照组,FCP、2hPCP、HOMA-β、FMD与HDL-C均高于对照组;治疗后6个月生活质量总分高于对照组,差异具有统计学意义(P<0.01);总有效率高于对照组,差异具有统计学意义(P<0.05)。结论: 二甲双胍和瑞舒伐他汀联合用于治疗初诊肥胖型2型糖尿病的疗效显著,具有借鉴意义。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	龚敏
	王爱华

关键词 ：二甲双胍, 瑞舒伐他汀, 肥胖型2型糖尿病

Abstract：Objective: To investigate the efficacy of combination of metformin and rosuvastatin in the treatment of newly diagnosed obese type 2 diabetes mellitus. Method: 90 newly diagnosed obese type 2 diabetic patients admitted to hospital from July 2015 to November 2016 were randomly divided into two groups. Patients in the control group were treated with metformin, while patients in the observation group were given rosuvastatin. The patients in the two groups were compared Patient disease-related parameters, overall treatment effect and quality of life. Result: The levels of BMI, SBP, FBG, 2hPG, HbAlc, HOMA-IR, IMT, TC, TG and LDL-C in the observation group were significantly lower than those in the control group, FCP, FMD and HDL-C were significantly higher than the control group; 6 months after treatment, the total quality of life scores were significantly higher than the control group, there was a significant difference (P <0.01); total effective rate was significantly higher than the control group, there was significant Difference (P <0.05). Conclusion: The combination of metformin and rosuvastatin is of great value in the treatment of newly diagnosed obesity type 2 diabetes.

Key words： Metformin Rosuvastatin Obese type 2 diabetes

基金资助:上海市浦东新区科委课题,(编号:PKJ2013-Y42)

引用本文:

龚敏, 王爱华. 二甲双胍和瑞舒伐他汀联合用于治疗初诊肥胖型2型糖尿病的疗效观察[J]. 河北医学, 2018, 24(2): 251-255.
GONG Min, WANG Aihua. The Efficacy of Metformin and Rosuvastatin in the treatment of Newly Diagnosed Type 2 Diabetes Mellitus. HeBei Med, 2018, 24(2): 251-255.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2018.02.019 或 http://www.hbyxzzs.cn/CN/Y2018/V24/I2/251

[1] 周斐.中西医结合治疗2型糖尿病合并高脂血症临床研究[J].河南中医,2017,37(8):1433~1435.
[2] 沈广礼,滕涛.中西医结合治疗2型糖尿病合并高脂血症临床研究[J].中医学报,2017,32(8):1423~1425.
[3] 李宁,施文科,姜一平,等.盐酸二甲双胍辅助治疗糖尿病高血脂的临床评价[J].中国现代药物应用,2015,9(20):123~124.
[4] 秦扬,王勉.中西医结合治疗2型糖尿病合并高脂血症43例疗效观察[J].海南医学,2014,42(16):2451~2452,2453.
[5] 南京,杨水祥.他汀类药物与新发糖尿病关系的研究进展[J].中国全科医学,2016,19(6):622~627.
[6] 王芳,吴红玲,黄镇河,等.瑞舒伐他汀对冠状动脉血流缓慢的糖尿病患者冠状动脉血流储备的影响[J].中国医药导报,2012,9(4):46~48.
[7] 耿娜,祁辉,刘静芹.瑞舒伐他汀治疗男性初诊2型糖尿病伴高脂血症的疗效及对血清vaspin水平的影响[J].河北医药,2016,45(18):2775~2777.
[8] 芮广跃,周燕.瑞舒伐他汀联合盐酸二甲双胍治疗糖尿病伴高血脂症临床观察[J].内蒙古中医药,2011,30(23):8~9.
[9] 王晔.瑞舒伐他汀治疗肥胖型2型糖尿病合并高脂血症48例[J].中国药业,2015,24(3):80~81.
[10] 孟桂莲,孟桂萍,刘秀英.联合中西医治疗2型糖尿病合并高脂血症患者的临床分析[J].中国民康医学,2015,28(14):79~80.
[11] 杨鑫,石家振,李新征,等.普罗布考联合二甲双胍对2型糖尿病伴血脂异常患者的疗效评价[J].中国药师,2017,20(3):485~488.
[12] 薛世荣,黄景文,罗韶金,等.瑞舒伐他汀对肥胖型2型糖尿病合并高脂血症患者高敏C反应蛋白及血脂的影响[J].实用临床医学(江西),2012,13(6):13~15.
[13] 杨放,刘雪梅.瑞舒伐他汀对高血脂伴糖尿病患者血管内皮细胞的保护作用[J].重庆医学,2011,40(18):1815~1816.
[14] 朱亚珅.瑞舒伐他汀联合依折麦布治疗老年糖尿病合并高脂血症的疗效观察[J].中国医院用药评价与分析,2016,16(9):1183~1185.
[15] 赵锦绣.荷丹片治疗2型糖尿病伴高脂血症的临床研究[J].天津药学,2015,27(4):40~43.
[16] 崔艳敏,孙璐,王淑敏,等.联合用药治疗初诊肥胖型2型糖尿病患者高敏C反应蛋白水平分析伥[J].医学综述,2015,22(3):536~538.